Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
Open Access
- 1 January 2010
- journal article
- Published by Springer Science and Business Media LLC in Cost Effectiveness and Resource Allocation
- Vol. 8 (1), 14
- https://doi.org/10.1186/1478-7547-8-14
Abstract
Intravenous immunoglobulin (IVIG) has demonstrated improvement in chronic inflammatory demyelinating polyneuropathy (CIDP) patients in placebo controlled trials. However, IVIG is also much more expensive than alternative treatments such as corticosteroids. The objective of the paper is to evaluate, from a Canadian perspective, the cost-effectiveness of IVIG compared to corticosteroid treatment of CIDP. A markov model was used to evaluate the costs and QALYs for IVIG and corticosteroids over 5 years of treatment for CIDP. Patients initially responding to IVIG could remain a responder or relapse every 12 week model cycle. Non-responding IVIG patients were assumed to be switched to corticosteroids. Patients on corticosteroids were at risk of a number of adverse events (fracture, diabetes, glaucoma, cataract, serious infection) in each cycle. Over the 5 year time horizon, the model estimated the incremental costs and QALYs of IVIG treatment compared to corticosteroid treatment to be $124,065 and 0.177 respectively. The incremental cost per QALY gained of IVIG was estimated to be $687,287. The cost per QALY of IVIG was sensitive to the assumptions regarding frequency and dosing of maintenance IVIG. Based on common willingness to pay thresholds, IVIG would not be perceived as a cost effective treatment for CIDP.Keywords
This publication has 24 references indexed in Scilit:
- Guidelines on the Use of Intravenous Immune Globulin for Hematologic ConditionsTransfusion Medicine Reviews, 2007
- Cost-effectiveness of alternative treatments for women with osteoporosis in CanadaCurrent Medical Research and Opinion, 2006
- Intravenous immunoglobulin for multifocal motor neuropathyCochrane Database of Systematic Reviews, 2005
- Cost–utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathyEuropean Journal of Neurology, 2003
- Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritisRheumatology, 2003
- Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 2001
- A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 1994
- Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.Journal of Neurology, Neurosurgery & Psychiatry, 1993
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatmentAnnals of Neurology, 1982